Rechallenge of afatinib for EGFR mutated non-small cell lung cancer previously treated with osimertinib
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000049225
- Lead Sponsor
- Shinshu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Having active multiple malignancies 2) Having active infectious disease (hepatitis B, hepatitis C, tuberculosis, HIV infection) 3) Pregnancy, breastfeeding or suspected of being pregnant 4) Undergoing concurrent anticancer therapy (chemotherapy, radiotherapy, immunotherapy, biological therapy, hormonal therapy) 5) Undergoing surgical treatment with organ removal within 28 days prior to registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate (ORR)
- Secondary Outcome Measures
Name Time Method Safety (incidence rate and severity of adverse events) Progression-free survival (PFS) Overall survival (OS)